Nuvasive, Inc.

Nuvasive, Inc., a San Diego-based medical device manufacturer, supplies spinal surgery implants, fusion devices, bone graft materials, and related surgical instruments to federal healthcare agencies as a prime contractor across 100% of recent awards, competing exclusively in full-and-open procurements without set-aside designations. The company operates two named subsidiaries — Nuvasive Clinical Services Monitoring, Inc. and Nuvasive Specialized Orthopedics, Inc. — and holds a single-award Blanket Purchase Agreement worth $8 million with the Defense Health Agency through March 2027 as its primary vehicle.

Nuvasive's federal customer base concentrates heavily on military medical procurement. The Defense Logistics Agency Troop Support Medical leads by volume and dollars (1,405 awards, $161.6 million combined potential value), followed by the Defense Health Agency (213 awards, $32.6 million), the Department of the Army Medical Command (300 awards, $22 million), the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 (625 awards, $20.7 million), and the Department of the Navy Bureau of Medicine and Surgery (408 awards, $10.4 million). These five agencies account for 78% of combined potential value across Nuvasive's federal footprint. Nuvasive competes across 30 distinct customer agencies, with concentration centered on the Defense Logistics Agency Medical Supply Chain, which funds the majority of delivery orders for spinal implants including RELINE-ONE, RELINE MAS IMPLANTS, MODULUS, SIMPLIFY, OSTEOCEL PRO, MAXCESS, and bone graft products such as ATTRAX. Recent award patterns show delivery orders ranging from approximately $100 to $84,000 with rapid completion timelines (frequently one to three weeks), reflecting urgent military medical supply requirements.

Vehicle positioning centers on the Defense Health Agency's $8 million IDIQ Blanket Purchase Agreement (BPA), awarded in March 2022 and expiring March 2027, as the primary contracting mechanism. Beyond that anchor vehicle, Nuvasive places task orders under the Defense Logistics Agency's Indefinite Delivery Contract SPE2DE21D7010 (1,403 task orders, $19.9 million combined potential value) and participates in the VA Prosthetic Implants and Appliances framework (355 task orders, $12 million combined potential value), which consolidates procurement of specialized medical devices across Veterans Health Administration facilities nationwide. Additional BPAs include HT001415A0017 (148 task orders, $7.3 million) and smaller agreements with the Army Medical Command.

Activity has remained relatively steady year over year across the historical record; 2022 and 2023 each generated roughly 366–379 awards, while 2024 and 2025 declined slightly to 281 and 286 awards respectively, with only 70 awards recorded through April 2026 year-to-date. Combined potential value across all 4,902 awards reaches $318.2 million, with $106.7 million obligated (34% of total potential). The footprint centers on Medical and Surgical Instruments, Equipment, and Supplies procurements (3,437 awards by PSC code), followed by Laboratory Equipment and Supplies (1,405 awards), reflecting Nuvasive's dual presence as both a surgical implant supplier and a source of spinal instrument kits and accessory equipment.

Nuvasive operates as a wholly-owned, for-profit corporate entity without SBA certifications and competes in unrestricted federal procurements. The company's award history spans from 2003 forward and is anchored to federal healthcare delivery: spinal surgery devices for Department of Defense and Department of Veterans Affairs medical treatment facilities, with secondary engagement through the Defense Health Agency and Navy Bureau of Medicine and Surgery. Nuvasive's federal strategy does not involve subcontracting; all awards reflect prime contractor delivery of medical devices manufactured and distributed from the San Diego headquarters location.